SYNTHIA (Merck KGaA)

Synthia (formerly known as Chematica) is a software platform developed by Merck KGaA that assists chemists in designing complex organic synthesis pathways. The tool leverages extensive chemical reaction databases alongside rule-based algorithms to calculate efficient routes toward target molecules. It helps research teams significantly reduce time spent in the preclinical and drug discovery phases.

The software enables retrosynthetic analysis, allowing users to analyze chemical syntheses starting from the target molecule backwards. It evaluates thousands of potential reaction pathways while considering costs, availability of starting materials, and experimental feasibility. Users can customize parameters such as reaction conditions and protection group strategies individually.

By integrating expert knowledge and validated data, the platform provides decision support for bench chemists. It serves not only to identify efficient pathways but also to prevent failed experiments through simulation-based pre-evaluation. The solution is primarily utilized within the pharmaceutical industry and academic research settings.

• Retrosynthetic Analysis — The tool breaks down target molecules into commercially available starting materials and proposes efficient synthesis routes. It evaluates the probability of success for each individual reaction step.
• Data-Driven Prediction — Synthia accesses an extensive database of curated chemical reactions. This data foundation is continuously updated and expanded by experts at Merck KGaA.
• Customizable Synthesis Parameters — Users can define specific constraints such as the number of synthetic steps, the price of starting materials, or chemical safety requirements. The system prioritizes routes based on these specific enterprise requirements.

The tool is primarily aimed at academic researchers in organic chemistry as well as industrial chemists in pharmaceutical and biotechnological research. It is designed for professionals who need to optimize complex synthesis plans.

A pharmaceutical research team wants to produce a novel molecule for cancer therapy. They enter the structure into Synthia and have the tool search for the most cost-effective and fastest synthesis pathways. The software identifies a previously unknown four-step route based on readily available chemicals. The chemist validates this proposal in the laboratory, reducing development time by several weeks.

• The tool is primarily aimed at academic researchers in organic chemistry as well as industrial chemists in pharmaceutical and biotechnological research. It is designed for professionals who need to optimize complex synthesis plans.
• A pharmaceutical research team wants to produce a novel molecule for cancer therapy.
• Retrosynthetic Analysis: The tool breaks down target molecules into commercially available starting materials and proposes efficient synthesis routes. It evaluates the probability of success for each individual reaction step.
• Data-Driven Prediction: Synthia accesses an extensive database of curated chemical reactions. This data foundation is continuously updated and expanded by experts at Merck KGaA.
• Customizable Synthesis Parameters: Users can define specific constraints such as the number of synthetic steps, the price of starting materials, or chemical safety requirements. The system prioritizes routes based on these specific enterprise requirements.

Synthia should not be used without relevant expertise in organic chemistry, as results must always be validated by an expert. It is also not suitable for users looking only for general chemical reference materials for simple tasks.

• Iktos — Paid · HQ: Paris, France · GDPR / EU